Novo Nordisk Shares Plunge as Alzheimer’s Trial Fails

Investor optimism for a breakthrough Alzheimer’s treatment from Novo Nordisk has evaporated following disappointing clinical trial results. The pharmaceutical giant’s attempt to demonstrate that its semaglutide compound—the active ingredient behind blockbuster drugs Ozempic and Wegovy—could slow cognitive decline in early-stage Alzheimer’s patients has ended in failure, sending shares tumbling to multi-year lows.

Clinical Study Misses Primary Goal

The EVOKE studies, whose results were highly anticipated by markets, failed to achieve their main objective. While Novo Nordisk reported some improvement in specific biomarkers, the treatment did not demonstrate meaningful clinical benefit for patients. This outcome prompted the company to cancel planned extensions of the research program.

Martin Holst Lange, head of development at Novo Nordisk, acknowledged the project’s “low probability of success” despite emphasizing the importance of investigating this potential application. The admission represents a significant setback for the company’s diversification efforts beyond its successful weight loss and diabetes treatments.

Market Reaction and Analyst Downgrades

Financial markets responded swiftly to the news. HSBC analysts immediately downgraded Novo Nordisk from “Buy” to “Hold” and slashed their price target from 445 to 300 Danish kroner. Market experts noted that the failed trial eliminates what many investors had considered a potential growth catalyst priced into the stock.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The share price reflects this disappointment, falling to levels not seen since 2021. The equity currently trades around €39, hovering dangerously close to its 52-week low as selling pressure continues.

Challenging Year Intensifies

The Alzheimer’s disappointment compounds what has become a difficult 2025 for Novo Nordisk. Since January, the company’s market value has declined by more than 54 percent. The pharmaceutical leader faces mounting challenges including intensified competition from Eli Lilly and unsuccessful acquisition attempts, such as the bidding war for biotechnology firm Metsera.

Internal leadership changes have yet to reverse the negative trend. New CEO Maziar Mike Doustdar, who replaced Lars Fruergaard Jørgensen, now faces the difficult task of restoring investor confidence without the potential of an Alzheimer’s treatment. Attention now shifts to defending market share in core business areas against growing pricing pressures.

Further details from the failed study are expected on December 3, though analysts suggest this information is unlikely to change the current negative sentiment surrounding the stock.